Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) Polymerase Inhibitors: Identification of (<i>S</i>)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1<i>H</i>-benzimidazole-4-carboxamide (A-966492), a Highly Potent and Efficacious Inhibitor
Vincent L. Giranda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Luis E. Rodrı́guez(Abbott Fund), Fritz G. Buchanan(AbbVie (United States)), Vered Klinghofer(Abbott Fund), Kennan C. Marsh(AbbVie (United States)), Yan Shi(Abbott Fund), Chang H. Park(AbbVie (United States)), Jennifer J. Bouska(Abbott Fund), Velitchka Bontcheva-Diaz(Abbott Fund), Donald J. Osterling(AbbVie (United States)), Gail Bukofzer(Institute of Cancer Research), Viraj B. Gandhi(Institute of Cancer Research), Jianchun Gong(Institute of Cancer Research), Elizabeth H. Fry, Eric F. Johnson(Pfizer (United States)), Amanda M. Olson(Abbott Fund), Xuesong Liu(Tianjin Institute of Pharmaceutical Research (China)), Yan Luo(AbbVie (United States)), Sheela A. Thomas(Abbott Fund), Gui‐Dong Zhu(Abbott Fund), Cherrie K. Donawho(Abbott Fund), David J. Frost(Abbott Fund)
Cited by 71
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776